Leaders of the House Energy and Commerce and Senate Finance committees today asked Health and Human Services Secretary Alex Azar to clarify by June 10 the agency’s plan and timeline for disbursing COVID-19 emergency relief funds to Medicaid-dependent providers.

“As the chairs and ranking members of the committees of jurisdiction over the Medicaid program, we are concerned that the delay in disbursing funds from the Public Health and Social Services Emergency Fund for Medicaid-dependent providers could result in long term financial hardship for providers who serve some of our most vulnerable populations,” wrote Energy and Commerce Chairman Frank Pallone Jr., D-N.J., and Ranking Member Greg Walden, R-Ore., and Senate Finance Chairman Charles Grassley, R-Iowa, and Ranking Member Ron Wyden, D-Ore. “It could also severely hamper their ability to continue to serve as essential providers amid the COVID-19 pandemic and beyond.”

AHA yesterday urged HHS to quickly distribute additional emergency funds to all hospitals, including hospitals serving high numbers of Medicaid and uninsured patients, among other recommendations.

Related News Articles

Headline
The White House Office of Management and Budget Jan. 29 rescinded a memo it issued two days earlier directing federal agencies to temporarily pause federal…
Headline
The White House Office of Management and Budget late Jan. 27 issued a memo directing federal agencies to temporarily pause federal grants, loans and other…
Headline
Respiratory illness activity remains high across the country, according to the latest data from the Centers for Disease Control and Prevention. Seasonal flu…
Headline
The Occupational Safety and Health Administration Jan. 13 announced that it terminated efforts to establish a final COVID-19 safety standard to protect workers…
Headline
The Department of Health and Human Services Dec. 10 amended the Public Readiness and Emergency Preparedness Act declaration for COVID-19, extending liability…
Headline
The Centers for Medicare & Medicaid Services Dec. 4 announced that drug manufacturers bluebird bio, inc. (manufacturer of Lyfgenia) and Vertex…